Wegovy (semaglutide) benefit application — coverage criteria
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 05.05.42 alerts
Get alerted when Policy 05.05.42 changes without checking for updates manually.
Monitor payer policy activity
Defines covered indications, prior authorization requirements, prescriber specialties, dosing limits, and medical necessity criteria for Wegovy (semaglutide) for members of the payer product(s). Affects prescribers and pharmacists requesting coverage for Wegovy.
No material clinical or coverage changes in this revision.
Coverage Criteria for Wegovy (semaglutide)
Initial approval — Major adverse cardiovascular event (MACE) reduction in established CVD with overweight/obesity
Covered when ALL of the following are met:
Alternative pathway — intolerance or inadequate response to standard classes
OR the member meets ALL of the following:
Initial and continuation approval — MASH
Covered when ALL of the following are met:
Not medically necessary
Coadministration with other semaglutide-containing products or with any other GLP‑1 receptor agonist is not recommended. The policy disallows use of Wegovy in combination with another targeted weight‑loss agent or another GLP‑1 receptor agonist; requests that indicate concomitant use with these products should be denied as outside the coverage criteria.
Wegovy (semaglutide) is considered not medically necessary for members who do not meet the specific criteria set forth in this policy. Members receiving samples or medication through the manufacturer’s patient assistance program must also meet the initial approval criteria to be eligible for coverage.
Coding and Quantity Limits
| No codes listed |
Provider Requirements and Prior Authorization
Prior Authorization Required
Prior authorization is required for the requested medication. Initial requests must be prescribed by or in consultation with an appropriate specialist as listed below.
- Prior authorization required for initial and continuation therapy
- Initial prescriber specialties required (see list below)
Prescriber Specialties (Initial Requests Only)
For the cardiovascular risk reduction indication, the prescriber must be one of the following specialists for initial requests: cardiologist, endocrinologist, lipid specialist, or cardiometabolic specialist. For the MASH indication, the prescriber must be a gastroenterologist, hepatologist, cardiometabolic specialist, or a primary care physician in consultation with one of the listed specialists.
- Cardiovascular Risk Reduction: Cardiologist; Endocrinologist; Lipid specialist; Cardiometabolic specialist
- MASH: Gastroenterologist; Hepatologist; Cardiometabolic specialist; Primary care with specialist consultation
Documentation Required for Cardiovascular Risk Reduction
Submit chart notes, medical record documentation, or claims history to support the cardiovascular indication and to demonstrate concurrent standard secondary prevention therapies. Provide current BMI (within 90 days) and documentation of established cardiovascular disease (prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease). Also include evidence of concomitant treatment with guideline-directed medical therapies (antiplatelet, lipid-lowering, antihypertensive).
- Chart notes or claims history confirming established CVD (prior MI, prior stroke, or symptomatic PAD)
- Current BMI documented within 90 days
- Documentation of concomitant guideline-directed medical therapies (antiplatelet, lipid-lowering, antihypertensive)
Continuation Therapy Documentation (Cardiovascular Indication)
For continuation requests for the cardiovascular indication, provide evidence of adherence (claims demonstrating ≥80% fill rate), absence of new diagnosis of type 2 diabetes, ongoing BMI ≥27 kg/m2, and that the member remains on standard of care cardiovascular therapies (antiplatelet, lipid‑lowering, antihypertensive).
- Adherence evidence: ≥80% refill rate by claims records
- Member has not developed type 2 diabetes
- Member remains on antiplatelet, lipid-lowering, and antihypertensive therapy
Not Medically Necessary When Criteria Not Met
Wegovy (semaglutide) is considered not medically necessary for members who do not meet the criteria outlined for the respective indications. Members receiving the medication as samples or via manufacturer patient assistance must meet initial approval criteria to continue therapy.
- Not medically necessary if criteria are not met
- Members on samples or manufacturer assistance must meet criteria for approval
Key Definitions
Background
Semaglutide (Wegovy) is FDA‑approved for weight reduction and to reduce major adverse cardiovascular events in adults with established cardiovascular disease plus overweight or obesity; it has also received accelerated approval for treatment of metabolic dysfunction‑associated steatohepatitis (MASH) with moderate to advanced fibrosis (F2‑F3). Use is intended in conjunction with a reduced‑calorie diet and increased physical activity, and the product should not be coadministered with other semaglutide‑containing products or any other GLP‑1 receptor agonist.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.